Aggribloc (Tirofiban Hcl) Injection

Description

Description

This page contains brief details about the drug tirofiban hcl, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Tirofiban hydrochloride (HCl) was initially approved by the U.S. Food and Drug Administration (FDA) on June 3, 1998.

Mechanism of Action of Tirofiban Hcl

Tirofiban hydrochloride (HCl)  works by inhibiting the glycoprotein IIb/IIIa receptor on the surface of platelets. This receptor plays a crucial role in platelet aggregation and clot formation. By blocking this receptor, tirofiban helps prevent the formation of blood clots.

Uses of Tirofiban Hcl

Tirofiban hydrochloride (HCl) is an antiplatelet medication with multiple clinical applications. Its primary uses include managing acute coronary syndromes (ACS), encompassing unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), by reducing the risk of coronary artery clot formation. During percutaneous coronary interventions (PCI) like angioplasty and stent placement, it prevents platelet aggregation and clot formation at the intervention site. Additionally, it is occasionally considered for managing thrombocytopenia, investigated for ischemic stroke cases, used in some coronary artery bypass grafting (CABG) procedures to minimize graft occlusion risk, and employed adjunctively in high-risk patients prone to clot formation.

Tirofiban Hcl Dosage available

Tirofiban hydrochloride (HCl) is typically administered intravenously (IV), giving it directly into a vein. It is usually administered in a healthcare setting, such as a hospital, where medical professionals can closely monitor the patient.